Aubagio

Janssen’s MS pill outshines Sanofi’s Aubagio in phase 3 trial
Janssen’s MS pill outshines Sanofi’s Aubagio in phase 3 trial
Pharmaforum
JNJ
Janssen
ponesimod
Sanofi
Aubagio
relapsing multiple sclerosis
Flag link:
Novartis’ ofatumumab meets primary endpoints in two phase 3 RMS trials
Novartis’ ofatumumab meets primary endpoints in two phase 3 RMS trials
Pharmaceutical Business Review
Novartis
ofatumumab
OMB157
Aubagio
clinical trials
relapsing multiple sclerosis
Flag link:
Janssen’s Ponesimod Finds Success in Head-to-Head Multiple Sclerosis Trial
Janssen’s Ponesimod Finds Success in Head-to-Head Multiple Sclerosis Trial
BioSpace
Janssen
JNJ
ponesimod
Sanofi
Aubagio
relapsing multiple sclerosis
Flag link:
How Aubagio became the most switched-to oral MS drug
How Aubagio became the most switched-to oral MS drug
Medical Marketing and Media
Aubagio
MS
multiple sclerosis
Sanofi
Flag link:
Sanofi to be a leader in MS, but not yet
Sanofi to be a leader in MS, but not yet
BioPharma Dive
Sanofi
MS
multiple sclerosis
Lemtrada
Aubagio
Flag link:
If copies of Teva's Copaxone hit, oral MS rivals could be the real threat
If copies of Teva's Copaxone hit, oral MS rivals could be the real threat
Fierce Pharma
Teva Pharmaceutical
Copaxone
MS
multiple sclerosis
generics
Tecfidera
Biogen
Gilenya
Novartis
Aubagio
Sanofi
Flag link:
Payers keep squeezing MS drugmakers--and they may just take their tactics elsewhere
Payers keep squeezing MS drugmakers--and they may just take their tactics elsewhere
Fierce Pharma
MS
multiple sclerosis
payers
Sanofi
Aubagio
Teva Pharmaceutical
Copaxone
Biogen
Tecfidera
Avonex
Flag link:
Sanofi Chipping Away At Biogen's MS Dominance
Sanofi Chipping Away At Biogen's MS Dominance
Investors.com
Sanofi
Biogen
MS
multiple sclerosis
Aubagio
Tecfidera
Flag link:
Sanofi calls out Genzyme, multiple sclerosis drug, as main drivers of growth again
Sanofi calls out Genzyme, multiple sclerosis drug, as main drivers of growth again
Bizjournals.com
Sanofi
Genzyme
MS
multiple sclerosis
Aubagio
earnings
Flag link:
Saskatchewan to fund treatment with AUBAGIO® for Relapsing Remitting Multiple Sclerosis
Saskatchewan to fund treatment with AUBAGIO® for Relapsing Remitting Multiple Sclerosis
Yahoo/CNW Group
Aubagio
multiple sclerosis
MS
Sanofi
Flag link:
Sanofi aims to grow Genzyme unit with new drugs and acquisitions
Sanofi aims to grow Genzyme unit with new drugs and acquisitions
Yahoo/Reuters
Sanofi
Genzyme
Aubagio
Lemtrada
Flag link:
Bring out the confetti: 7 of 2013's launches will join Sovaldi, Tecfidera in blockbuster land
Bring out the confetti: 7 of 2013's launches will join Sovaldi, Tecfidera in blockbuster land
Fierce Pharma Marketing
drug launches
Tecfidera
Sovaldi
Aubagio
Imbruvica
Tivicay
Breo Ellipta and Anoro Ellipta
Kadcyla
Invokana
Pomolyst
Flag link:
Analysis of FDA side-effect reports flags Sanofi, Celgene meds
Analysis of FDA side-effect reports flags Sanofi, Celgene meds
Fierce Pharma
Celegene
FDA
Sanofi
side effects
Pomalyst
Tecfidera
Biogen Idec
Aubagio
Flag link:
Sanofi’s Aubagio Wins Final Approval From U.K. Cost Agency NICE
Sanofi’s Aubagio Wins Final Approval From U.K. Cost Agency NICE
Bloomberg
Sanofi
Aubagio
NICE
MS
multiple sclerosis
Flag link:
Sanofi wins EU approval for second MS treatment
Sanofi wins EU approval for second MS treatment
Reuters
Sanofi
Europe
MS
multiple sclerosis
Aubagio
Lemtrada
Flag link:
European Commission Approves Genzyme’s Once-Daily, Oral Multiple Sclerosis Treatment Aubagio (teriflunomide)
European Commission Approves Genzyme’s Once-Daily, Oral Multiple Sclerosis Treatment Aubagio (teriflunomide)
Yahoo/BusinessWire
Genzyme
multiple sclerosis
Aubagio
MS
Flag link:
Biogen investors encouraged by ruling on rival drug, shares jump
Biogen investors encouraged by ruling on rival drug, shares jump
Marketwatch
Biogen Idec
Sanofi
Aubagio
Tecfidera
MS
multiple sclerosis
Flag link:
Aubagio EU Backing Comes With Generic Worries
Aubagio EU Backing Comes With Generic Worries
Seeking Alpha
Aubagio
Europe
generics
Sanofi
MS
multiple sclerosis
Flag link:
Biogen, Baxter, Sanofi, Gilead Win EU Endorsements
Biogen, Baxter, Sanofi, Gilead Win EU Endorsements
Investors.com
Biogen Idec
Baxter International
Sanofi
Gilead
Europe
BG-12
Tecfidera
Aubagio
HyQvia
Halozyme
Stribild
Flag link:
2013 Should Be Interesting for Multiple Sclerosis Drugs
2013 Should Be Interesting for Multiple Sclerosis Drugs
Motley Fool
MS
multiple sclerosis
Teva
Copaxone
Rebif
Pfizer
Merck KGaA
Biogen Idec
Avonex
Bayer
Betaseron
Novartis
Extavia
Sanofi
Tysabri
Aubagio
Elan
Gilenya
BG-12
Flag link:

Pages